SMZ1.F Sino Biopharmaceutical Limited

Healthcare Biotechnology Frankfurt Exchange
0.6546 EUR
Close of Nov 12, 2026
0.4615 0.7777
Market cap
EUR 11.6B
P/E
32.7x
P/B
2.52x
ROE
7.6%
Dividend yield
2.53%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is SMZ1.F undervalued?

Graham number
Price0.6546
Graham value0.3420
Premium91.4%

SMZ1.F trades 91.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sino Biopharmaceutical Limited fundamental analysis

No fundamental analysis for Sino Biopharmaceutical Limited yet.

Sino Biopharmaceutical Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, ben…

Full company profile